Product Name: Fyn-pY213+pY214
Product Number: AB-PK644
Size: 25 µg      Price:89.00
      $US
Target Full Name: Fyn proto-oncogene-encoded protein-tyrosine kinase

Target Alias: Fyn; Fyn oncogene related to SRC, FGR, YES; Kinase Fyn; MGC45350; P59-Fyn; P59-Fyn; SLK; SYN; hCG_34806; RP1-66H14.1-003; CCDS5094.1; ENSG00000010810

Product Type Specific: Protein kinase phosphosite-specific antibody

Antibody Code: PK644

Antibody Target Type: Phosphosite-specific

Antibody Phosphosite: Y213+Y214

Protein UniProt: P06241

Protein SigNET: P06241

Antibody Type: Polyclonal

Antibody Host Species: Rabbit

Antibody Immunogen Source: Human Fyn sequence peptide Cat. No.: PE-04AMP99

Antibody Immunogen Sequence: NGG(pY)(pY)ITT(bA)C

Antibody Immunogen Description: Corresponds to amino acid residues N210 to T217; In the SH2 domain. Two of This is the major in vivo phosphorylation sites in Fyn.

Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.This antibody was also subject to negative purification over phosphotyrosine-agarose.

Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.

Antibody Concentration: 0.5 mg/ml

Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol

Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.

Product Use: Western blotting | Antibody microarray

Antibody Dilution Recommended: 2 µg/ml for immunoblotting

Antibody Potency: Medium immunoreactivity of a target-sized protein by Western blotting in A431 cells. Very strong immunoreactivity with immunogen peptide on dot blots.

Antibody Species Reactivity: Human

Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 50-60 kDa.

Antibody Specificity: High

Antibody Cross Reactivity: Medium to strong cross-reactive proteins of ~250, 180, 150, 80 and 45 kDa are detected in A431 cells.

Related Product 1: Fyn-pY213+pY214 blocking peptide

Related Product 2: Fyn-ANT pan-specific antibody (Cat. No.: AB-NK065-2)

Related Product 3: Fyn-pY531 phosphosite-specific antibody (Cat. No.: AB-PK645)

Related Product 4: FynSubtide - Fyn protein kinase substrate peptide

Scientific Background: Fyn is a protein-tyrosine kinase of the TK group and Src family. It is a non-receptor kinase that mediates cell growth, survival, and adhesion. This kinase is highly expressed and widely distributed in most tested human tissues. Fyn is inhibited by phosphorylation at Y531. Fyn has been shown to phosphorylate Dab1, an intracellular adaptor protein that interacts with amyloid precursor protein (APP) and apoE receptor 2 (apoEr2). The interaction of Fyn and Dab1 regulates the phosphorylation, trafficking, and processing of APP and apoEr2. Fyn can interact with Fyn-binding protein and the p85 subunit of PI3K. It has been shown to be part of a protein complex involving DCC and FAK, which is downstream of Netrin-1, a pathway important in promoting both axonal outgrowth and axonal guidance in path finding. Fyn may be an oncoprotein (OP) based on its similarity to other Src family kinases that are known oncoproteins. Fyn expression has been shown to be significantly increased in Chronic Myelogenous Leukemia (CML). Knockdown of Fyn with shRNA slows leukemia cell growth, inhibits clonogenicity, and leads to increased sensitivity to imatinib. Fyn has also been linked with the development of lung squamous cell carcinomas (LSCC), melanomas (metastatic) and epilepsy. The active form of the protein kinase normally acts to promote tumour cell proliferation. Fyn has been linked with estrogen-receptor negative breast cancer, which is related to breast and colon cancer, and it may affect breast, lymph node, or lung tissues. Insertional mutagenesis studies in mice also support a role for this protein kinase in mouse cancer oncogenesis.
Figure 1. Epitope mapping of Fyn-pY213+pY214 antibody with similar phosphopeptides on dot blots.


Figure 2. Identification of phosphosites related to Fyn-pY213+pY214.